In comparisons between Vioxx and Celebrex, Merck would like to focus on the two drugs 'labels.
Vioxx has an indication for treatment of acute pain ; Celebrex does not _ it has been approved for the treatment of rheumatoid arthritis and osteoarthritis.
Some new approaches come from surprising directions.
Dr. Kenneth D. Brandt of the University of Indiana is overseeing a large federally sponsored trial of doxycycline, a synthetic version of the antibiotic tetracycline, in people with osteoarthritis or at high risk for the disease.
``It's one of the most exciting developments in the treatment of arthritis in 25 years because we potentially will be able to treat people for their pain and inflammation without them suffering the side effects,'' says Rubin.
That was five years ago, plenty of time to have recovered from successful carpal tunnel surgery on both wrists and to become much more aware of the lingering pain of arthritis.
Merck, the world's largest drug company, will be playing catch-up to Monsanto Co.'s Celebrex drug, which won U.S. approval on Dec. 31.
Like Celebrex, Merck is looking to get approval for Vioxx to treat osteoarthritis, which affects more than 16 million Americans.
But much of the research on glucosamine and chondroitin compounds is flawed and probably overstates their benefits so more study is needed to determine if they really help achy joints, according to the analysis in Wednesday's Journal of the American Medical Association.
In the last couple of years, however, American researchers have become curious.
